1 |
SUNG H, FERLAY J, SIEGEL R L, et al.. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J. Clin., 2021, 71(3):209-249.
|
2 |
LEE Y B, MIN J K, KIM J G, et al.. Multiple functions of pyruvate kinase M2 in various cell types[J]. J. Cell. Physiol., 2021,237(1):128-148.
|
3 |
MAZUREK S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells[J]. Int. J. Biochem. Cell. Biol., 2011, 43(7):969-980.
|
4 |
HUANG P, ZHAO X, XIAO W, et al.. 18F-fluorodeoxyglucose uptake predicts PKM2 expression in lung adenocarcinoma[J]. Oncotarget, 2017, 8(24):39618-39626.
|
5 |
XIAO H, ZHANG L, CHEN Y, et al.. PKM2 promotes breast cancer progression by regulating epithelial mesenchymal transition[J/OL]. Anal. Cell. Pathol., 2020, 2020:8396023[2021-06-01]. .
|
6 |
LI Y H, LI X F, LIU J T, et al.. PKM2, a potential target for regulating cancer[J]. Gene, 2018, 668:48-53.
|
7 |
AZOITEI N, BECHER A, STEINESTEL K, et al.. PKM2 promotes tumor angiogenesis by regulating HIF-1alpha through NF-kappaB activation[J/OL]. Mol. Cancer, 2016, 15:3 [2021-6-1]. .
|
8 |
GU Z, XIA J, XU H, et al.. NEK2 promotes aerobic glycolysis in multiple myeloma through regulating splicing of pyruvate kinase[J/OL]. J. Hematol. Oncol., 2017, 10(1):17 [2021-06-01]. .
|
9 |
PANCHABHAI S, SCHLAM I, SEBASTIAN S, et al.. PKM2 and other key regulators of Warburg effect positively correlate with CD147 (EMMPRIN) gene expression and predict survival in multiple myeloma[J]. Leukemia, 2017, 31(4):991-994.
|
10 |
AHMED A S, DEW T, LAWTON F G, et al.. M2-PK as a novel marker in ovarian cancer. A prospective cohort study[J]. Eur. J. Gynaecol. Oncol., 2007, 28(2):83-88.
|
11 |
CHRISTOFK H R, VANDER HEIDEN M G, WU N, et al.. Pyruvate kinase M2 is a phosphotyrosine-binding protein[J]. Nature, 2008, 452(7184):181-186.
|
12 |
KEFAS B, COMEAU L, ERDLE N, et al.. Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells[J]. Neuro. Oncol., 2010, 12(11):1102-1112.
|
13 |
SHI HS, LI D, ZHANG J, et al.. Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice[J]. Cancer Sci., 2010, 101(6):1447-1453.
|
14 |
GUO W, ZHANG Y, CHEN T, et al.. Efficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer model[J]. J. Cancer. Res. Clin. Oncol., 2011, 137(1): 65-72.
|
15 |
WANG C, ZHANG S, LIU J, et al.. Secreted pyruvate kinase M2 promotes lung cancer metastasis through activating the integrin Beta1/FAK signaling pathway[J]. Cell Rep., 2020, 30(6):1780-1797.
|
16 |
CHUNG-FAYE G, HAYEE B, MAESTRANZI S, et al.. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation[J]. Inflamm. Bowel. Dis., 2007, 13(11):1374-1378.
|
17 |
YU S, ZANG W, QIU Y, et al.. Deubiquitinase OTUB2 exacerbates the progression of colorectal cancer by promoting PKM2 activity and glycolysis[J]. Oncogene., 2022, 41(1): 46-56.
|
18 |
YIN C, LU W, MA M, et al.. Efficacy and mechanism of combination of oxaliplatin with PKM2 knockdown in colorectal cancer[J/OL]. Oncol. Lett., 2020, 20(6):312[2021-06-01]. .
|
19 |
DE ROSA V, IOMMELLI F, MONTI M, et al.. Reversal of warburg effect and reactivation of oxidative phosphorylation by differential inhibition of EGFR signaling pathways in non-small cell lung cancer[J]. Clin. Cancer Res., 2015, 21(22):5110-5120.
|
20 |
WEI Y, WANG D, JIN F, et al.. Pyruvate kinase type M2 promotes tumour cell exosome release via phosphorylating synaptosome-associated protein 23[J/OL]. Nat. Commun., 2017, 8:14041[2021-6-1]. .
|
21 |
WHITESELL L, LINDQUIST S L. HSP90 and the chaperoning of cancer[J]. Nat. Rev. Cancer, 2005, 5(10):761-772.
|
22 |
EUSTACE B K, JAY D G. Extracellular roles for the molecular chaperone, hsp90[J]. Cell Cycle, 2004, 3(9):1098-1100.
|
23 |
TIAN Y, WANG C, CHEN S, et al.. Extracellular Hsp90alpha and clusterin synergistically promote breast cancer epithelial-to-mesenchymal transition and metastasis via LRP1[J/OL]. J. Cell. Sci., 2019, 132(15): cs228213 [2021-6-1]. .
|
24 |
WONG D S, JAY D G. Emerging roles of extracellular Hsp90 in cancer[J]. Adv. Cancer Res., 2016, 129:141-163.
|
25 |
VUORILUOTO K, HAUGEN H, KIVILUOTO S, et al.. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer[J]. Oncogene, 2011, 30(12):1436-1448.
|
26 |
HAMABE A, KONNO M, TANUMA N, et al.. Role of pyruvate kinase M2 in transcriptional regulation leading to epithelial-mesenchymal transition[J]. Proc. Natl. Acad. Sci. USA, 2014, 111(43):15526-15531.
|
27 |
AMIN S, YANG P, LI Z. Pyruvate kinase M2: A multifarious enzyme in non-canonical localization to promote cancer progression[J]. Biochim. Biophys. Acta. Rev. Cancer, 2019, 1871(2):331-341.
|